Needham & Company LLC reissued their buy rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a report published on Tuesday morning, Benzinga reports. Needham & Company LLC currently has a $22.00 price objective on the technology company’s stock. COGT has been the subject of several other reports. HC Wainwright reissued a buy […]
Needham & Company LLC reiterated their buy rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $22.00 price target on the technology company’s stock. Other analysts also recently issued research reports about the stock. HC Wainwright reissued a buy rating […]
Logos Global Management LP decreased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 9.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,000,000 shares of the technology company’s stock after selling 100,000 shares during the period. […]
Ghost Tree Capital LLC reduced its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 31.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 550,000 shares of the technology company’s stock after selling 250,000 shares during the quarter. Cogent […]